NewsfeedFollowed Companies

Eli Lilly's Competitors, Revenue, Number of Employees, Funding and Acquisitions

Eli Lilly develops, produces and markets pharmaceutical products for health care professionals, patients and consumers.

E... Read more

Based on data from Eli Lilly's latest SEC filings

Annual Revenue

Based on data from Eli Lilly's latest SEC filings

Employees

David A. Ricks's photo - Chairman & CEO of Eli Lilly

Chairman & CEO

David A. Ricks

CEO Approval Rating

69/100

OVERVIEW

Founded:

1876

Headquarters:

IndianapolisIndiana

Status:

PublicIndependent Company of NYSELLY

Industry Sector:

Pharmaceuticals

SIC Code:

2834NAICS listing »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Bristol Myers Squibb a competitor of Eli Lilly?

I don't know

Trending News for Eli Lilly and Eli Lilly's Competitors

November 19, 2019

Pharma Manufacturing

Pfizer nabs FDA approval for Humira biosim

Abrilada is the fifth Humira biosimilar approved in the U.S. and will join generics from Mylan, Samsu... See more »

November 18, 2019

Pharmaceutical Business Review

Qtrilmet approved in EU to treat type-2 diabetes

The approval is based on data from five Phase III trials which evaluated combinations of Forxiga (dap... See more »

November 18, 2019

Business Medical Dialogues

Bristol Myers Squibb gets FTC okay for acquiring Celgene

"The Commission has ordered Bristol Myers Squibb to divest Otezla to preserve BMS's incentive to cont... See more »

Competitive Analysis

TOP COMPETITORS OR ALTERNATIVES

AbbVie is one of Eli Lilly's top rivals. AbbVie is a Public company that was founded in 2012 in North Chicago, Illinois. Like Eli Lilly, AbbVie also works within the Pharmaceuticals industry. Compared to Eli Lilly, AbbVie has 8,680 fewer employees.

Amgen is seen as one of Eli Lilly's biggest rivals. Amgen was founded in 1980 in Thousand Oaks, California. Amgen competes in the Biotechnology industry. Amgen generates $1.5B less revenue than Eli Lilly.

AstraZeneca is one of Eli Lilly's top competitors. AstraZeneca was founded in 1999, and its headquarters is in Cambridge, England. Like Eli Lilly, AstraZeneca also operates in the Pharmaceuticals sector. AstraZeneca has 22,420 more employees than Eli Lilly.

RANK

COMPANY

LEADERSHIP

CEO SCORE

EMPLOYEES

TOTAL FUNDING

REVENUE

David A. Ricks

Chairman & CEO

- -
38,680
$0
$24.9B
1

Richard A. Gonzalez

Chairman & CEO

69/100
30,000
- -
$32.9B
2

Robert A. Bradway

Chairman & CEO

75/100
19,200
$19M
$23.4B
3

Pascal Soriot

CEO

69/100
59,700
- -
$21.9B
4

Jose E Almeida

Chairman & CEO

89/100
50,000
- -
$11.1B
5

Michel Vounatsos

CEO

57/100
7,800
- -
$14.2B
6

Giovanni Caforio

Chairman & CEO

75/100
23,300
- -
$24.2B
7

Mark J. Alles

Chairman & CEO

70/100
8,852
- -
$17B
8

Daniel O’Day

Chairman & CEO

60/100
11,000
$86.3M
$22.4B
9

Emma Walmsley

CEO

61/100
99,827
- -
$39.4B
10

Alex Gorsky

Chairman & CEO

69/100
135,100
- -
$81.7B
The top 10 competitors in Eli Lilly's competitive set are AbbVie, Amgen, AstraZeneca, Baxter, Biogen, Bristol Myers Squibb, Celgene, Gilead, GSK and Johnson & Johnson. Together they have raised over 105.2M between their estimated 443.6K employees. Eli Lilly has 38,680 employees and is ranked 5th among it's top 10 competitors. The top 10 competitors average 43,950.

Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$24.9B

Eli Lilly's revenue is the ranked 4th among it's top 10 competitors. The top 10 competitors average 28.5B. Over the last four quarters, Eli Lilly's revenue has decreased by 37.1%. Specifically, in Q3 2019's revenue was $5.5B; in Q2 2019, it was $5.6B; in Q1 2019, it was $5.1B; in Q4 2018, Eli Lilly's revenue was $8.7B.

Acquisitions

COMPANY ACQUIRED
ACQUISITION DATE
AMOUNT
DESCRIPTION
Loxo Oncology, Inc.

Jan 2019

Source »
$8B
Loxo Oncology develops and markets genomic medicines for the treatment of cancer.
ARMO BioSciences, Inc.

May 2018

Source »
$1.6B
ARMO BioSciences develops immunotherapies for the treatment of cancer, fibrosis, hypercholesterolemia and inflammatory diseases.
Colucid Pharmaceuticals, Inc.

Jan 2017

Source »
$960M
Colucid is focused on developing drug for the acute treatment of migraine headaches and CNS disorders.
Boehringer Ingelheim Vetmedica, Inc.

Oct 2016

Source »
undisclosed
Boehringer Ingelheim is a pharmaceutical firm that discovers and develops drugs for animals.
Avid Radiopharmaceuticals

Dec 2011

Source »
undisclosed
-

These are all the companies that Eli Lilly has acquired. Eli Lilly has acquired 7 companies and its latest acquisition was Loxo Oncology, Inc. in Jan 2019. Loxo Oncology develops and markets genomic medicines for the treatment of cancer.

Investments

COMPANY

DESCRIPTION

AMOUNT

INVESTMENT DATE

ROUND

EXIT DATE

Avidity Biosciences develops and markets oligonucleotide-based therapeutics to treat muscle disorders.
$100M
Nov 12, 2019
Series C
-
Mission Bay Capital is a venture capital firm specializing in seed and early-stage investments.
$60M
Sep 15, 2019
Investment Fund
-
NextCure is a biopharmaceutical company that researches and develops immuno-medicines for the treatment of cancer.
$93.4M
Nov 12, 2018
Series B
-
Dicerna is a developer of investigational ribonucleic acid interference therapeutics for liver, cardiovascular and viral infectious diseases.
$100M
Oct 28, 2018
Equity
Jan 29, 2014
Magnolia NeuroSciences develops and provides neuroprotective medicines for alzheimer disease and other neurological conditions.
$31M
Aug 02, 2018
Series A
-

These are all the companies that Eli Lilly has invested in. Eli Lilly has invested 7 companies and its latest investment was Loxo Oncology, Inc. in Jan 2019. Loxo Oncology develops and markets genomic medicines for the treatment of cancer.

Eli Lilly News

November 14, 2019PharmaTimes

Lilly, Boehringer initiate Jardiance heart failure trial

The study is the sixth Phase III trial of the drug's programme.... See more »
November 14, 2019San Diego Business Journal

Avidity Biosciences Raises $100M Round

Avidity Biosciences bagged a $100 million series C round to work on a pipeline of preclinical program... See more »
November 13, 2019PharmaLive

Eli Lilly's Taltz Hits the Mark in Phase III Inflammatory Study

Eli Lilly is planning to seek another regulatory approval for Taltz after the medication hit the prim... See more »
November 11, 2019FiercePharma

Eli Lilly's Taltz extends its head-to-head Humira beat with 52-week psoriatic arthritis data

Standing toe-to-toe with giants is nothing to sniff at, but bagging an outright advantage is somethin... See more »
November 7, 2019MarketScreener

Lilly Announces the Pricing Terms of its Cash Tender Offer for Up to $2,000,006,000 Aggregate Principal Amount of Its Outstanding Debt Securities

(marketscreener.com) INDIANAPOLIS, Nov. 7, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) ann... See more »
November 7, 2019firstwordpharma

Lilly Announces the Early Tender Results and Upsizing of Its Pending Cash Tender Offer to Up to $2,000,006,000 Aggregate Principal Amount of Its Outstanding Debt Securities

INDIANAPOLIS, Nov. 7, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today the earl... See more »
November 5, 2019Inside Indiana Business

Lilly, Boehringer Ingelheim 'Modernize' Relationship

Indianapolis-based Eli Lilly and Co. (NYSE: LLY) and Germany-based Boehringer Ingelheim have restruct... See more »

Eli Lilly Blogs

April 30, 2015LILLY BLOG

Polio and the Power of Partnership

See more »
April 29, 2015LILLY BLOG

Producing Innovation: What Does It Take?

See more »
April 28, 2015LILLY BLOG

Why IP and Data Confidentiality Need Protection

See more »
April 28, 2015LILLY BLOG

Embracing the Power of Diversity

See more »
April 25, 2015LILLY BLOG

A Recipe For A Healthier Tomorrow

See more »
April 22, 2015LILLY BLOG

Keep Calm and Recycle On

See more »
April 21, 2015LILLY BLOG

Minority Health: 30 Years After Heckler

See more »

Eli Lilly Press Releases

November 4, 2019PR Newswire

Lilly to Participate in Credit Suisse 28th Annual Healthcare Conference

INDIANAPOLIS, Nov. 4, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in the C... See more »
September 30, 2019centralcharts

Adocia Announces Receipt of USD 14.3 million Payment from Eli Lilly Following Arbitration Conclusion and the Decision by Mutual Consent with Eli Lilly to Conclude the Civil Case

Regulatory News: Adocia (Paris:ADOC) (Euronext Paris: FR0011184241 - ADOC), a clinical stage biopharm... See more »
September 20, 2019Korea Newswire

Consistent cardiovascular benefits shown with empagliflozin treatment regardless of the number of controlled cardiovascular risk factors

Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced results of a post-hoc anal... See more »
September 11, 2019StreetInsider

Unimpeded by Allergan's Botox Dominance, Amgen/Novartis' Aimovig, Teva's Ajovy, and Eli Lilly's Emgality Use at the Patient Level is More Robust Within the Episodic Migraine Segment Than Physicians Ar

EXTON, Pa., Sept. 11, 2019 /PRNewswire/ -- Contributing physicians appear to underestimate their use ... See more »
August 27, 2019BriefingWire

Alan Davis Management strikes gold.

James Elliot celebrates first acquisition of 2019 : Alan Davis Management strikes gold.... See more »
August 14, 2019Newswise

Sanford Burnham Prebys expands collaboration with Lilly to investigate immunological therapies

Sanford Burnham Prebys Medical Discovery Institute today announced a three-year extension to its exis... See more »
August 8, 2019StreetInsider

Lilly Malaysia and Lilly Singapore Recognized as One of the Best Places to Work For 2019

KUALA LUMPUR, Malaysia & SINGAPORE--(BUSINESS WIRE)-- Eli Lilly (Malaysia) Sdn Bhd Malaysia and Eli L... See more »

Eli Lilly Videos

October 15, 2019Eli Lilly Youtube Channel

"Lilly Global Day of Service: Healthy Lives, Minds & Communities" on YOUTUBE

See more »
October 10, 2019Eli Lilly Youtube Channel

"Caroline's Story - Ankylosing Spondylitis" on YOUTUBE

See more »
October 2, 2019Eli Lilly Youtube Channel

"Lilly's Commitment to Continuous Manufacturing" on YOUTUBE

See more »
September 25, 2019Eli Lilly Youtube Channel

"Lilly Experience for Teachers in STEM (LETS)" on YOUTUBE

See more »
August 30, 2019Eli Lilly Youtube Channel

"Pursuit of Innovations in Pain Management" on YOUTUBE

See more »
August 30, 2019Eli Lilly Youtube Channel

"Early Career Professionals at Lilly" on YOUTUBE

See more »
July 31, 2019Eli Lilly Youtube Channel

"Patient Perspective: Improving Research" on YOUTUBE

See more »

Social Statistics

Headquarters

Lilly Corporate Center

Indianapolis, Indiana46285

317-276-2000

Driving Directions »

Trending Companies

Summary

ABOUT

Overview

Eli Lilly and Company (NYSE: LLY) manufactures and sells pharmaceutical products for health care professionals, patients, and consumers. Is an American global pharmaceutical company with headquarters located in Indianapolis, Indiana. The company also ...

CEO

Eli Lilly's Chairman & CEO, David A. Ricks, currently has an approval rating of 69%. Eli Lilly's primary competitors are AbbVie, Amgen & AstraZeneca.

Website

lilly.com

Frequently Asked Questions about Eli Lilly

  1. When was Eli Lilly founded?

    Eli Lilly was founded in 1876

  2. Who is Eli Lilly's CEO?

    Eli Lilly's CEO is David A. Ricks

  3. How much revenue does Eli Lilly generate?

    Eli Lilly generates $24.9B in revenue

  4. How much funding does Eli Lilly have?

    Eli Lilly has historically raised $0 in funding

  5. Where is Eli Lilly's headquarters?

    Eli Lilly's headquarters is in Indianapolis Indiana, USA

  1. How many employees does Eli Lilly have?

    Eli Lilly has 38,680 employees

  2. What sector does Eli Lilly operate in?

    Eli Lilly is in Pharmaceuticals

  3. Who are Eli Lilly's competitors?

    Eli Lilly's top competitors are AbbVie, Amgen, AstraZeneca

  4. Who has Eli Lilly invested in?

    Eli Lilly's has invested in companies such as Avidity Biosciences, Mission Bay Capital, NextCure
Stay up-to-date with the latest news on Eli Lilly